Results 111 to 120 of about 58,344 (230)

Cardiovascular Disease (CVD) Risk in Women With Endometriosis: A Comprehensive Meta‐Analysis

Clinical Cardiology, Volume 49, Issue 8, August 2026.
ABSTRACT Background Cardiovascular disease (CVD) remains the leading cause of mortality globally. Emerging evidence indicates that cardiovascular risk in women is frequently underestimated, underscoring the importance of recognizing sex‐specific contributors.
Maneeth Mylavarapu, Jeffry Samuel, Ravitej Thandi, Rizwan Mubashir, Vaishnavi Reddy Veeranagari, Aly Barakat, Joao Ferreira de Barros Neto, Alaa Osman, Sudeeshna Thiyagarajan, Reem Mohamed, Muhammad Junaid Hassan   +10 more
wiley   +1 more source

Dynamic Urinary Albumin/Creatinine Ratio Patterns Predict Adverse Outcomes in HFpEF: TOPCAT Cohort Analysis

Clinical Cardiology, Volume 49, Issue 8, August 2026.
Among 746 HFpEF patients in TOPCAT, latent class modeling identified three uACR trajectories: stable, decreasing, and fluctuating high. The fluctuating high trajectory independently predicted the composite of cardiovascular death, aborted cardiac arrest, or heart failure hospitalization, and adding trajectory data modestly improved risk prediction ...
Weiping Xiao, Zhiyan Wang, Di‐en Yan, Min‐an Peng, Xinyuan Zhou   +4 more
wiley   +1 more source

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 531-541, August 2026.
CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao, Jean G. Malavé, Joseph S. Rossi, Francesco Franchi, Ellen C. Keeley, Dominick J. Angiolillo, George A. Stouffer, Larisa H. Cavallari, Craig R. Lee   +8 more
wiley   +1 more source

The Potential Role of MicroRNAs as Cardioprotective Agents During Cardioplegia: A Preliminary Qualitative Systematic Review

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aims Recent advancements in gene expression studies have shed light on the role of non‐coding RNAs in negatively regulating mRNA and inhibiting mRNA translation. Given the significant impact of miRNAs on cardiovascular function, our review aims to comprehensively explore their contribution to mitigating heart injury and their ...
Maryam Baniani, Ali Dabbagh, Pourya Shokri, Firoozeh Madadi   +3 more
wiley   +1 more source

The Therapeutic Potential of H2S‐Releasing Platforms in Cardiovascular Applications

Journal of Biomedical Materials Research Part B: Applied Biomaterials, Volume 114, Issue 8, August 2026.
The Therapeutic Potential of H2S‐Releasing Platforms. ABSTRACT Once known as a toxic gas, hydrogen sulfide (H2S) is now making its way into many therapeutic applications. Similar to its other fellow endogenous gasotransmitters, nitric oxide and carbon monoxide, H2S is a small gas with a short half‐life, making it extremely capable of penetrating ...
Tia N. Shorter, Elizabeth J. Brisbois
wiley   +1 more source

Divergent Atrial Transcriptomic Signatures in Diabetic and Nondiabetic Atrial Fibrillation

Journal of Arrhythmia, Volume 42, Issue 4, August 2026.
Diabetes alters the atrial transcriptome in atrial fibrillation, characterized by enhanced mitochondrial ATP synthesis, suppressed immune and inflammatory pathways, and distinct miRNA expression profiles, suggesting metabolic and epigenetic remodeling of the atrial substrate.
Kenshi Yoshimura, Yuya Kiriake, Hiroki Osanai, Mengyan Wei, Shinichiro Kume, Tatsuki Kurokawa, Masaki Morishima, Ryusuke Suzuki, Shinji Miyamoto, Katsushige Ono   +9 more
wiley   +1 more source

Optimizing CABG in Brazil: Why Superspecialization and Personalized Care Matter Now. [PDF]

Braz J Cardiovasc Surg
Mejia OAV, Segalote RC, Deininger MO, Mioto BM, Gomes WJ.   +4 more
europepmc   +1 more source

Cardio‐Protective Effect of GLP‐1 Agonists in OSA Patients: A Study of Cardiovascular Risk

Laryngoscope Investigative Otolaryngology, Volume 11, Issue 4, August 2026.
ABSTRACT Objective Obstructive sleep apnea (OSA) is highly associated with obesity and often results in significant cardiovascular complications. This study aimed to assess cardiovascular outcomes in OSA patients treated with GLP‐1 agonists (GLP1a) versus CPAP.
Morgan Lane, Alex Jin, Boston Andersen, Alec Kadrie, Sage Hebert, Evan Thomson, M. Boyd Gillespie   +6 more
wiley   +1 more source

Mortality Outcome Post-MI after PCI and CABG Interventions. [PDF]

Glob Heart
Al-Naqdi MMA, Alkhammasi MLM, Al-Naqdi BMA.   +2 more
europepmc   +1 more source

Bioresorbable Scaffolds for Coronary Arteries: Where Do We Stand Today?

VIEW Medicine, Volume 1, Issue 1, August 2026.
Bioresorbable coronary scaffolds are moving from thick strut pitfalls to thinner, stronger, healing‐oriented designs. Integrating advances in materials, guided implantation with preparation, size, and postdilation steps, and resorption aligned to healing, we synthesize clinical evidence and chart a roadmap toward intelligent, transient platforms ...
Junya Matsuda, Tatsuya Watanabe, Satoshi Yuhara, John M. Kelly, Hirotsugu Kurobe, Toshiharu Shinoka   +5 more
wiley   +1 more source